BioPharmSignal logoBioPharmSignal

Biotech News

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

PTC Therapeutics, Inc. (PTCT)PTC Therapeutics, Inc.Earnings

– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue guidance raised to $960 to $990 million – – Sephience™ (sepiapterin) Q3 2026

Related news

PTCTPTC Therapeutics, Inc.2026-07-30 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PTCTPTC Therapeutics, Inc.2026-10-15 12:00 EST

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

CAPRCapricor Therapeutics2026-11-03 14:00 EST

Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10

CAPRCapricor Therapeutics2026-08-13 20:05 EST

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TARAProtara Therapeutics2026-11-06 13:00 EST

Protara Therapeutics Announces Third Quarter 2026 Financial Results and Provides a Business Update

RAREUltragenyx Pharmaceutical2026-10-27 20:05 EST

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

MNPRMonopar2026-08-12 13:30 EST

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

TARAProtara Therapeutics2026-08-11 12:00 EST

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

ABEOAbeona Therapeutics2026-08-06 11:30 EST

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

RAREUltragenyx Pharmaceutical2026-08-04 20:05 EST

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

View all latest news

PTC Therapeutics, Inc.

Rare-Disease Medicines PTC Therapeutics discovers, develops and commercializes medicines for children and adults with rare disorders. Its portfolio spans metabolic, neurologic and neuromuscular diseases. Commercial Portfolio Sephience, or sepiapterin, is a therapy for phenylketonuria and represents a growing global commercial franchise....

Recent company news

PTCTPTC Therapeutics, Inc.2026-11-03 12:00 EST

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program

PTCTPTC Therapeutics, Inc.2026-11-02 13:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

PTCTPTC Therapeutics, Inc.2026-10-30 20:30 EST

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PTCTPTC Therapeutics, Inc.2026-10-29 20:01 EST

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

PTCTPTC Therapeutics, Inc.2026-10-15 12:00 EST

PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026

Stock data

Close
65.67 USD
Market cap
5.66B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States